**Humber and North Yorkshire area prescribing committee**

**AGENDA ITEM NO:**

|  |  |
| --- | --- |
| **Date of Meeting:** |  |
| **Title of paper:** |  |
| **Director Sponsor:** |  |
| **Author:** |  |
| **Author contact details:** |  |
| **Author declarations of interests:** |  |

|  |
| --- |
| **Executive Summary****Please provide no more than a one page summary and include key points** |
|  |
| **This item is presented to HNY APC for:** |[ ]  ***Decision*** |
|  |[ ]  ***Discussion*** |
|  |[ ]  ***Information*** |
|  |[ ]  ***Assurance*** |
| **HNY APC is asked to**:  |
| **Indicate how this item aligns with ICB strategic aims** (please tick all that apply) |
| Improve outcomes in population health and healthcare |[ ]
| Tackle inequalities in outcomes, experience and access |[ ]
| Enhance productivity and value for money |[ ]
| Help the NHS support broader social and economic development  |[ ]
| **Indicate how these aims will be measured**: |
| **This proposal has the support of all HNY ICB localities** | [ ]  Yes | [ ]  NoPlease list any locality that has not confirmed support; give extra detail in the exec summary as appropriate |
| **This proposal has the support of all HNY ICB hospital trusts, as applicable** | [ ]  Yes | [ ]  NoPlease list any Trust that has not confirmed support; give extra detail in the exec summary as appropriate |

|  |
| --- |
| **IMPLICATIONS** Please provide further detail in the executive summary above, where appropriate |
| FinanceIf yes, complete [appendix 1](#appendix_one) | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Commissioning | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Quality | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| HR | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Legal / regulatory | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Data protection / IG | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Health inequality / equalityIf an equality impact is possible, complete [appendix 2](#appendix_two) | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Conflict of interest  | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| Sustainability | **Yes** [ ]  **No** [ ]  **N/A** [ ] Rationale**:** |
| **OTHER ASSESSED RISK:** Nothing additional. |

**Appendix 1: Financial implications summary**

|  |
| --- |
| **Please provide details of any financial implications of this proposal***Fill in section 1 OR section 2.*  |
| **1. What are the anticipated implementation costs of this intervention?** Please include a costed estimate impact for the ICB and per locality |  |
| **Is this intervention a like for like switch?**  | Yes [ ] Please fill in **section 1** | No [ ] Please go to **section 2** |
| **1a) what are the costs of the medicines involved?** |  |
| **1b) Will this intervention benefit primary or secondary care or both?** Please provide detail (e.g. patient experience / process / clinical outcomes) |  |
| **2. Is this a “spend to save” initiative?**  | Yes [ ] Please fill in **section 2** | No [ ]  |
| **2a) Detail the source of funds and the anticipated payback period** |  |
| **2b) Will this intervention benefit primary or secondary care or both?** Please provide detail (e.g. patient experience / process / clinical outcomes) |  |
| **2c) Will this intervention present as an activity saving or a reduction in prescribing costs?**Please provide detail |  |
| **2d) Provide a costed estimate of any savings over the full payback period** |  |

**Appendix 2: Equality Impact assessment**

|  |
| --- |
| **Equality Impact Assessment** Indicate whether the decision has a positive or negative effect on any groups of people with protected characteristics, and on Human Rights |
| **Protected Characteristic** | **Positive** | **Negative** | **Explanation** |
| Age |[ ] [ ]   |
| Disability |[ ] [ ]   |
| Gender |[ ] [ ]   |
| Pregnancy or maternity |[ ] [ ]   |
| Race |[ ] [ ]   |
| Religion and belief |[ ] [ ]   |
| Sexual orientation |[ ] [ ]   |
| Other vulnerable group |[ ] [ ]   |
| Human Rights |[ ] [ ]   |
| If you have answered that there is a negative impact to any one of the questions above, please explain what has been done or will be done to mitigate this.  |
|  |